Physician
The Howard Young Medical Center, INC.
The Howard Young Medical Center, INC. was paid $2.91M by Medicaid between Jan 2018 and Dec 2024, across 99 billing codes. Its largest line is 96361, Intravenous infusion, hydration; each additional hour — 12% of everything it billed.
33Billing provider infoTHE HOWARD YOUNG MEDICAL CENTER, INC.
WOODRUFF, WI 54568
WOODRUFF, WI 54568
33aNPI1134183171assigned 04/14/2006
33bProvider typeHospitalist Physician
28Total paid$2.91M
24GClaims94,377
24DCodes billed99
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Hospitalist Physician providers in Wisconsin
Rank by total paid#2 of 35
Median peer was paid$14K
This provider vs. median210×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official YANG, JERRY controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 16,961 | $536K | |
| 2019 | 17,671 | $607K | |
| 2020 | 13,308 | $480K | |
| 2021 | 12,450 | $336K | |
| 2022 | 11,182 | $310K | |
| 2023 | 13,718 | $378K | |
| 2024incomplete | 9,087 | $261K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 96361 | Intravenous infusion, hydration; each additional hour | 12% | 2,645 | 1,997 | $360K |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 12% | 3,634 | 3,281 | $343K |
| 41899 | Unlisted procedure, dentoalveolar structures | 8.2% | 798 | 553 | $240K |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 8.2% | 4,000 | 3,469 | $238K |
| 80053 | Comprehensive metabolic panel | 6.3% | 7,031 | 5,755 | $183K |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 6.1% | 3,892 | 3,347 | $177K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 4.5% | 1,064 | 981 | $132K |
| 99001 | 3.7% | 1,914 | 1,615 | $107K | |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | 3.4% | 1,593 | 1,114 | $98K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 3.0% | 1,464 | 804 | $87K |
| 70450 | Computed tomography, head or brain; without contrast material | 2.7% | 1,136 | 985 | $78K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | 2.6% | 1,559 | 1,292 | $76K |
87 more codes
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | 2.4% | 545 | $71K |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | 2.0% | 699 | $59K |
| 99213 | Doctor's office visit, returning patient (routine) | 1.8% | 969 | $52K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | 1.8% | 461 | $52K |
| 80048 | Basic metabolic panel (calcium, ionized) | 1.8% | 2,331 | $51K |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | 1.8% | 342 | $51K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 1.8% | 7,180 | $51K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 1.6% | 723 | $46K |
| 81001 | <1% | 3,360 | $28K | |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 175 | $26K |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 705 | $23K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 1,299 | $22K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 1,166 | $21K |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | <1% | 186 | $21K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 352 | $19K |
| 80306 | <1% | 958 | $18K | |
| 84484 | <1% | 2,168 | $16K | |
| 81025 | <1% | 422 | $14K | |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 494 | $13K |
| 83735 | <1% | 2,312 | $11K | |
| 80061 | Lipid panel | <1% | 782 | $10K |
| 85610 | <1% | 1,730 | $9K | |
| 87070 | <1% | 227 | $9K | |
| 81003 | <1% | 1,083 | $8K | |
| 83690 | <1% | 1,263 | $7K | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 191 | $7K |
| 99214 | Doctor's office visit, returning patient (more involved) | <1% | 101 | $7K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 110 | $6K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 1,815 | $6K |
| G0378 | Hospital observation service, per hour | <1% | 230 | $4K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 1,230 | $4K |
| 83605 | <1% | 518 | $4K | |
| 82947 | <1% | 216 | $3K | |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 2,611 | $3K |
| 73630 | <1% | 179 | $3K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 350 | $3K |
| 85651 | <1% | 884 | $3K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 4,682 | $2K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 42 | $2K |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 72 | $2K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 178 | $2K |
| 85730 | <1% | 475 | $2K | |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 63 | $2K |
| 87040 | <1% | 123 | $1K | |
| 86140 | <1% | 370 | $1K | |
| 84703 | <1% | 88 | $1K | |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 16 | $1K |
| 85027 | <1% | 238 | $1K | |
| 84145 | <1% | 68 | $1K | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 1,932 | $997.96 |
| 71045 | Radiologic examination, chest; single view | <1% | 1,544 | $988.02 |
| 86803 | <1% | 55 | $911.27 | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 30 | $834.59 |
| 80076 | <1% | 94 | $776.30 | |
| 73610 | <1% | 27 | $656.08 | |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 25 | $578.22 |
| 87807 | <1% | 18 | $571.86 | |
| G0399 | Home sleep test (hst) with type iii portable monitor, unattended; minimum of 4 channels: 2 respiratory movement/airflow, 1 ecg/heart rate and 1 oxygen saturation | <1% | 16 | $509.95 |
| 85652 | <1% | 184 | $393.57 | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 14 | $366.85 |
| 82550 | <1% | 82 | $350.63 | |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 3,278 | $340.54 |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 12 | $234.84 |
| 86618 | <1% | 12 | $191.34 | |
| 83880 | <1% | 14 | $170.77 | |
| 85379 | <1% | 29 | $169.59 | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 1,876 | $134.43 |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 12 | $118.92 |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 734 | $94.13 |
| 85007 | <1% | 29 | $84.85 | |
| 87077 | <1% | 17 | $75.15 | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 1,082 | $74.49 |
| 87186 | <1% | 15 | $71.52 | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 1,953 | $24.83 |
| J2704 | Injection, propofol, 10 mg | <1% | 12 | $3.53 |
| J2270 | Injection, morphine sulfate, up to 10 mg | 0% | 546 | $0.00 |
| A4641 | Radiopharmaceutical, diagnostic, not otherwise classified | 0% | 14 | $0.00 |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | 0% | 17 | $0.00 |
| A9270 | Non-covered item or service | 0% | 1,384 | $0.00 |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | 0% | 19 | $0.00 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | 0% | 789 | $0.00 |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | 0% | 91 | $0.00 |
| J3010 | Injection, fentanyl citrate, 0.1 mg | 0% | 764 | $0.00 |
| 96376 | 0% | 40 | $0.00 | |
| Q9963 | High osmolar contrast material, 350-399 mg/ml iodine concentration, per ml | 0% | 15 | $0.00 |
| J1170 | Injection, hydromorphone, up to 4 mg | 0% | 66 | $0.00 |
| J2060 | Injection, lorazepam, 2 mg | 0% | 24 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialYANG, JERRY (SVP & CHIEF FINANCIAL OFFICER)
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.